Loading resource…

Dr. W.G. Herrington
The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of patients with chronic kidney disease. The study enrolled patients with varying degrees of kidney function and aimed to evaluate the impact of empagliflozin on the progression of kidney disease and related outcomes. The findings suggest that empagliflozin may slow the decline in kidney function and reduce the risk of adverse outcomes compared to placebo.
No account needed